Altimmune acquires Spitfire Pharma
The company announced earlier this summer that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH).
Spitfire, a portfolio company of Presidio Partners, was founded by John J. Nestor, Jr., Ph.D. and Velocity Pharmaceutical Development, LLC, for the sole purpose of developing the NASH drug candidate, SP-1373.
"NASH is a significant unmet need. There are no approved treatments available, and prevalence is growing worldwide as a consequence of an expanding obesity epidemic. Compelling preclinical data generated by Spitfire suggests that ALT-801 could reverse obesity, a primary cause of NASH, thereby reducing excess liver fat, inflammation and fibrosis associated with the disease" said Dr. Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "The addition of this exciting product candidate to our portfolio is a transformative transaction for Altimmune."
An upfront payment of $5 million
Spitfire shareholders will receive an upfront payment of $5 million in Altimmune common stock and will be eligible to receive an additional $8 million in future regulatory and clinical milestones payable in cash or common stock. Spitfire shareholders are also eligible to receive up to $80 million in sales-based milestones. The issuance of common stock to satisfy the milestone payments is subject to stockholder approval in accordance with Nasdaq rules.
ALT-801
ALT-801 builds on the company's liver disease expertise being developed in Altimmune's HepTcell program for treating chronic hepatitis B and continues to build and leverage the Company's deep knowledge of developing novel peptide-based therapeutics.
Altimmune
Spitfire Pharma
New findings about the gut microbiome
Zealand Pharma's CSO leaves the company
Isofol Seeks Marketing Partner
Isofol, a clinical stage pharmaceutical company based in Gothenburg, Sweden, has launched a global program to identify one or more strategic partners for commercialization of its Modufolin(R) chemotherapy asset. The Sage Group, which is based in Europe, the USA and Asia, has been appointed by Isofol to assist the company.…
Enzymatica signs agreement with Actavis
Enzymatica and the international pharmaceuticals company, Actavis, have signed a letter of intent on the sale of Enzymatica's cold treatment product, ColdZyme Mouth Spray, on the Nordic market. Under the agreement, the product will be on sale in around 3,200 pharmacies and a large number of stores, including health food…
Moberg Pharma acquires OTC brands in the US from Bayer HealthCare
Moberg Pharma has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources. The acquired…
BMS acquires Cormorant Pharmaceuticals
Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The acquisition gives Bristol-Myers Squibb full rights to Cormorant's HuMax-IL8 antibody program and the lead candidate HuMax-IL8, a Phase 1/2 monoclonal…